Haemonetics Non Operating Income Net Other from 2010 to 2026
| HAE Stock | USD 57.50 1.96 3.30% |
Non Operating Income Net Other | First Reported 2010-06-30 | Previous Quarter -2.6 M | Current Value -2.1 M | Quarterly Volatility 2 M |
Check Haemonetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Haemonetics' main balance sheet or income statement drivers, such as Interest Expense of 13.7 M, Total Revenue of 1.6 B or Gross Profit of 940.1 M, as well as many indicators such as Price To Sales Ratio of 2.14, Dividend Yield of 0.0098 or PTB Ratio of 2.81. Haemonetics financial statements analysis is a perfect complement when working with Haemonetics Valuation or Volatility modules.
Haemonetics | Non Operating Income Net Other | Build AI portfolio with Haemonetics Stock |
Analyzing Haemonetics's Non Operating Income Net Other over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Non Operating Income Net Other has evolved provides context for assessing Haemonetics's current valuation and future prospects.
Latest Haemonetics' Non Operating Income Net Other Growth Pattern
Below is the plot of the Non Operating Income Net Other of Haemonetics over the last few years. It is Haemonetics' Non Operating Income Net Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Haemonetics' overall financial position and show how it may be relating to other accounts over time.
| Non Operating Income Net Other | 10 Years Trend |
|
Non Operating Income Net Other |
| Timeline |
Haemonetics Non Operating Income Net Other Regression Statistics
| Arithmetic Mean | (10,094,374) | |
| Coefficient Of Variation | (62.15) | |
| Mean Deviation | 4,836,822 | |
| Median | (10,926,000) | |
| Standard Deviation | 6,273,512 | |
| Sample Variance | 39.4T | |
| Range | 20.6M | |
| R-Value | (0.70) | |
| Mean Square Error | 21.7T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (863,816) | |
| Total Sum of Squares | 629.7T |
Haemonetics Non Operating Income Net Other History
About Haemonetics Financial Statements
Haemonetics stakeholders use historical fundamental indicators, such as Haemonetics' Non Operating Income Net Other, to determine how well the company is positioned to perform in the future. Although Haemonetics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Haemonetics' assets and liabilities are reflected in the revenues and expenses on Haemonetics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Haemonetics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Operating Income Net Other | -13.2 M | -13.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:Check out the analysis of Haemonetics Correlation against competitors. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Will Health Care Equipment & Supplies sector continue expanding? Could Haemonetics diversify its offerings? Factors like these will boost the valuation of Haemonetics. Market participants price Haemonetics higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Haemonetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.284 | Earnings Share 3.63 | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Haemonetics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.